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Abstract: The emergence of multidrug resistant (MDR) infections and the shortage of new therapeutic
options have made colistin, a polymyxin antibiotic, the main option for the treatment of MDR
Gram-negative bacterial infections in the last decade. However, the rapid onset of renal damage often
prevents the achievement of optimal therapeutic doses and/or forces the physicians to interrupt
the therapy, increasing the risk of drug resistance. The proper management of colistin-induced
nephrotoxicity remains challenging, mostly because the investigation of the cellular and molecular
pharmacology of this drug, off the market for decades, has been largely neglected. For years, the
renal damage induced by colistin was considered a mere consequence of the detergent activity of this
drug on the cell membrane of proximal tubule cells. Lately, it has been proposed that the intracellular
accumulation is a precondition for colistin-mediated renal damage, and that mitochondria might be
a primary site of damage. Antioxidant approaches (e.g., ascorbic acid) have shown promising results
in protecting the kidney of rodents exposed to colistin, yet none of these strategies have yet reached
the bedside. Here we provide a critical overview of the possible mechanisms that may contribute to
colistin-induced renal damage and the potential protective strategies under investigation.
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1. Introduction
Colistin or polymyxin E was isolated in Japan from Bacillus polymyxa var. colistinus by Koyama [1].
From a chemical point of view, colistin shares a common backbone with polymyxin B: A cyclic
heptapeptide possessing a tripeptide side chain acylated at the amino terminus by a fatty acid tail.
Position 6 is occupied by D-phenylalanine in polymyxin B and by D-leucine in colistin (Figure 1).
Colistin exerts its bactericidal effects mainly by disrupting the cell membrane integrity of the
Gram-negative bacteria: through electrostatic interaction and cationic displacement (Ca++ and Mg++)
of the lipopolysaccharide (LPS), colistin disturbs the stability of the membrane and increases its
permeability, leading to the leakage of the cell content, triggering cell death pathways. Other
bactericidal mechanisms of colistin may be (i) the neutralization of LPS, the endotoxin of Gram-negative
bacteria and/or (ii) the inhibition of bacterial respiration [2,3].
In most of the reports published in its first decade of existence, colistin was demonstrated to
have at least comparable potency to polymyxin B with less incidence of adverse reactions, especially
nephrotoxicity, thus outranking polymyxin B and the other polymyxins with its wider therapeutic
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index. Colistin was introduced in the clinic in 1961 with the expectation, by the scientific community,
of finally filling the void in the treatment of challenging infections such as those from antibiotic resistant
Pseudomonas aeruginosa [4]. Shortly thereafter, side-by-side studies showed that colistin was not better
tolerated than the other polymyxins, scaling down colistin use to levels comparable with polymyxin
B [5,6]. With the discovery and approval of new, more tolerable antibiotics, colistin, like the other
polymyxins, was gradually dismissed from clinical use due to the high incidence of nephrotoxicity.
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Because of the increasing incidence of multidrug-resistant (MDR) bacterial infections, such as
methicillin-resistant Staphylococcus aureus, vancomycin i t t enterococci and some Gram-negative
bacill like Pseudomonas aeruginosa, Acinetobacter bauma nii and Enteroba teriaceae, colistin has regained
significant inter st. Currently, colistin is co sidered the last-resort antibiotic in many areas where MDR
is observed i medic e [7,8]. However optimal admin stration of this antibiotic and the appropriate
management of th related n phrotoxicity remain challenging, ostly because the pharmacology of
this drug is still l rgely undescribed. We provide an overview of the cli ical and histopathological
c aracteristics f colistin-induced kidne damage an a critical review f the possible mechanisms
underlying colistin-induc d nephrotoxicity. Sources for this review w re obt ined through extensiv
literature searches of p blicatio s browsing P bMed. The ma n keywo ds used for searches
colistin, polymyxin E, nephrotoxicity, drug-induced kidney injury, and mitochondria. Only papers
published in the English language were considered.
2. Drug-Induced Nephrotoxicity: An Overview
According to the clinical practice guidelines from Kidney Disease: Improving Global Outcomes
(KDIGO), nephrotoxicity, in patients with normal renal function (serum creatinine of 1.3 mg/dL in
women and 1.5 mg/dL in men), is apparent when one of the following are fulfilled: (i) increase in
serum creatinine by ≥0.3 mg/dL within 48 h, (ii) increase in serum creatinine to ≥1.5 times baseline,
which is known or presumed to have occurred within the prior 7 days, and/or (iii) urine volume
<0.5 mL/kg/h for 6 h [9,10]. With the increasing use of medications over the years, drugs have become
a substantial contributor to nephrotoxicity etiopathogenesis, including acute kidney injury (AKI) and
chronic kidney disease (CKD). Prospective studies have established that drug-related nephrotoxicity
accounts for 14–26% of all acute kidney injury cases in the adult population [11–13]. Analogously, 16%
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of the pediatric cases of AKI that required hospitalization have been attributed to the use of drugs [14].
Notably, there is no consensus on the definition of drug-induced kidney injury (DIKI), leading to
challenges in the recognition and reporting thereof, especially for drugs not previously associated with
kidney damage. Therefore, the incidence of DIKI may be underestimated. To harmonize the guidelines
for the diagnosis of DIKI, a novel framework to approach drug-induced nephrotoxicity, focused on Risk
assessment, early Recognition, targeted Response, timely Renal support and Rehabilitation coupled
with Research (the 6R approach) has been proposed. For more details on this matter, we refer to the
original work by Awdishu and Mehta [15].
One kidney contains over one million nephrons, the functional units of the kidney. Each nephron
is composed of a glomerulus and a tubule. The glomerulus filters the blood retaining cells and large
proteins, producing an ultrafiltrate mainly composed by small molecules, from nutrients to ions.
The ultrafiltrate enters the tubule in which highly specialized cells at various segments (proximal
tubule, Henle’s loop and distal tubule) contribute to modify the native urine by removing substances
from the tubular fluid (reabsorption) or adding substances to the tubular fluid (secretion). Filtration,
reabsorption, and secretion regulate the homeostasis of water, minerals, electrolytes, protons and
nutrients, and clears the body of drugs, contrast agents and toxins [16].
The kidney damage induced by drugs can involve any of the nephron segments (Figure 2).
Some drugs can cause a glomerular lesion (e.g., pamidronate, non-steroidal anti-inflammatory drugs,
anti-angiogenetic drugs), others preferentially target the tubule. The injury can be cell-specific
(e.g., proximal tubule cells) or can be the result of a nonselective insult to multiple cell types and damage
of the epithelial cells throughout the tubule. The pathophysiology of drug-induced nephrotoxicity
includes changes in glomerular hemodynamics, tubular cell toxicity, inflammation, crystal nephropathy
(stone formation), rhabdomyolysis (breakdown of muscle fibers), and thrombotic microangiopathy
(ischemic capillaries) [17–19]. An acute tubular damage of necrotic nature at the level of the proximal
tubule cells is considered the primary event in colistin-induced kidney injury [20].
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Figure 2. Main sites of drug-induced kidney injury. Schematic representation of a nephron,
the functional unit of the kidney. Each nephron is composed of a glomerulus and a tubule. The
glomerulus filters the blood, producing an ultrafiltrate mainly composed by small molecules, from
nutrients to ions. The ultrafiltrate enters the tubule in which at various segments (proximal tubule,
Henle’s loop and distal tubule) it is modified to obtain the final urine in the collecting duct.
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3. Clinical and Histopathological Manifestations of Colistin-Induced Nephrotoxicity
While nephrotoxicity was the main reason for colistin’s dismissal from clinical use in the first
place, more recent clinical studies have diminished this issue by observing a lower incidence of kidney
damage in patients treated with colistin as compared with initial studies. This discrepancy might be
explained by the lack of common criteria to define renal function impairment and by the increased
use of purer drug preparations [7,21]. The use of the KDIGO criteria to define AKI, rarely applied to
patients receiving colistin, may help to better define the incidence of colistin-induced kidney damage.
In a recent study, among 249 patients treated with intravenous colistin, rates of AKI using these clinical
practice guideline criteria were 12% and 29% at 48 h and 7 days, respectively, from the initiation
of the treatment. Seven percent of patients required renal replacement therapy following colistin
initiation [22].
Another confounding factor is represented by the wide spectrum of dosing regimens used
throughout the world, likely because the majority of dosing strategies currently in use represent the
legacy of past empirical approaches, in the absence of accurate pharmacokinetic and pharmacodynamic
data. Recent clinical studies demonstrated that most of the currently recommended colistin regimens
are sub-optimal and that much higher doses should be administered to maximize the antibiotic activity
and reduce the development of resistance [23]. In a recent study, after administering a loading dose,
the authors utilized the maintenance dose algorithm to target a colistin steady-state concentration of
2.5 mg/L. From a pharmacodynamics perspective, this target concentration would be sub-optimal,
with minimal bactericidal activity (based on the minimum inhibitory concentration calculated in vitro).
However, the reported 44% rate of renal toxicity discouraged the authors from recommending
higher target concentrations to increase the therapeutic response and to reduce the onset of colistin
resistance [24].
Clinical manifestations of colistin nephrotoxicity include a decrease in creatinine clearance,
as well as potential proteinuria, cylindruria (presence of casts in the urine), or oliguria (low output
of urine) [25–31]. Nonetheless, assessment of histological abnormalities associated with colistin
treatment, extensively reported in animal models, appear to be the most accurate way to diagnose
colistin nephrotoxicity, albeit not doable within a clinical setting. Kidneys of rats treated with colistin
for 7 days are marked by tubular dilation and epithelial cell vacuolation, tubular epithelial cell necrosis
with numerous casts, but without evidence for an inflammatory response or fibrous cicatrisation [20].
There is little data regarding the best biomarker for the early detection of colistin nephrotoxicity.
Use of the serum creatinine level for the estimation of the glomerular filtration rate (GFR) has some
limitations, such as dependence on sex, age, nutrition and body mass, and is likely to reflect an
already advanced damage. Studies in animal models showed that Cystatin C and kidney injury
molecule 1 (KIM-1) might be more reliable markers than plasma creatinine to monitor renal function
during colistin treatment [20,31]. Cystatin C is a cysteine protease inhibitor that is synthesized by
all nucleated cells and freely filtered by the glomerulus, reabsorbed completely in proximal tubules,
and not secreted under normal, healthy conditions [32]. KIM-1 is a phosphatidylserine receptor with
an immunoglobulin-like domain that is expressed in normal proximal tubular epithelial cells and
overexpressed upon acute tubular injury. Urinary KIM-1 has been reported to be specific to proximal
tubular damage [33].
4. The Detergent Theory
Like the other members of the polymyxin family, colistin’s mechanism of action can be described
by the “Shai-Matsuzaki-Huang (SMH) model”: antimicrobial peptides exert their bactericidal effects
via interaction with the lipopolysaccharide (LPS) moiety of the membrane of Gram-negative bacteria
(Figure 1). Electrostatic interaction with the negatively charged phospholipid headgroups and cationic
displacement (Ca++ and Mg++) lead to disturbances in the stability of the membrane and an increase in
its permeability, leakage of cell content, and cell death [34–36]. In 1970, Kunin found that polymyxin
B and colistin sulfate tend to lose their antimicrobial activity when co-incubated with kidney tissue
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homogenate from rabbit. Sodium colistimethate, a less nephrotoxic species, was not sensitive to
the incubation with the very same homogenate. The author concluded that polymyxin B and
colistin sulfate, unlike colistimethate, are depleted by electrostatic interactions with the excess of
anionic phospholipids contained in the homogenates. As for bacterial membranes, such interactions
would destabilize the plasma membrane of eukaryotic cells with resulting leakage and death [37].
This “detergent theory” is mentioned in many reviews to explain colistin-induced nephrotoxicity, yet
it is difficult to reconcile with the different biochemistry and physiology of prokaryotic and eukaryotic
membranes (Figure 3). While both prokaryotic and eukaryotic membranes are enriched in anionic
phospholipids, especially the renal brush-border membranes, their spatial organization within the
lipid bilayer is substantially different. In bacterial membranes, the anionic phospholipids mainly
localize at the outer leaflet with the negatively charged headgroup exposed to the extracellular milieu.
In eukaryotic cells, negatively charged phospholipids are segregated into the inner leaflet of the
membrane with the headgroup pointing towards the intracellular space. Hence, the interaction of
the antibiotics with the plasma membrane of mammalian cells is limited in comparison with that
of bacterial membranes [38]. Consistently, Mohamed and coworkers recently reported that colistin
exposure induces haemolysis of red blood cells in culture but only at extracellular concentrations of
50 µM or higher, levels not achievable with the current colistin therapeutic regimens [39]. Furthermore,
the effect observed by Kunin using tissue homogenates was not specific for the kidney. Similar results
were obtained using liver or heart homogenates, tissues that are usually not sensitive to colistin in vivo.
It is possible that the homogenization process renders the negatively charged phospholipids more
accessible to colistin than in the intact cells [37]. Finally, it should be kept in mind that cholesterol,
a component of the eukaryotic bilayer absent in bacterial membranes, tends to reduce the antimicrobial
peptide activity by stabilizing the lipid bilayer or by directly interacting with the peptide [34,38].
Does the detergent theory still stand considering these fundamental differences in cell membrane
composition? If so, a resulting prerequisite for colistin to be able to disrupt the plasma membrane
integrity of eukaryotic cells would be an efficient uptake of the drug. Intracellular colistin would then
have direct access to the acidic phospholipid components of the membrane and might indeed disrupt
the membrane integrity.
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Figure 3. Lipid composition and distribution of prokaryotic and eukaryotic plasma membrane.
Negatively charged phospholipids are enriched in the outer layer of prokaryotic membranes and
in the inner layer of eukaryotic membranes. Cholesterol, a constituent of eukaryotic cells, stabilizes
and protects the membrane from the colistin detergent activity.
5. Membrane Transport of Colistin
Tubular epithelial cells express a wide range of transporters, some of them representing an
important route of cell entrance for several drugs ( .g., gentamicin and cisplatin). These transporters
are highly expressed at the plasma m mbranes ( ither the basolateral or the brush border) f the
tubular epithelium and sensitize the tubul r cells to a number of drugs or other xenobiotics [40].
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Colistin is extensively reabsorbed by the proximal tubule cells. Due to its polycationic nature at
physiological pH values, colistin diffuses only poorly across the lipid bilayer. Thus, its tubular
reabsorption is likely to involve one or more transport systems. Nevertheless, studies focused on the
identification of the molecular mechanism of transport of colistin across the cell membrane are sparse
and relatively recent. [41]. Currently, both endocytic processes and facilitative transport have been
shown to contribute to the uptake of colistin across the apical side of proximal tubule cells (Figure 4).
In 2013, Suzuki and colleagues reported that colistin is reabsorbed by the proximal tubular cells
upon binding to megalin, a 600 kDa glycoprotein highly expressed at the apical membrane of the
proximal tubule cells. Wistar rats displayed a reduction in the renal accumulation and a simultaneous
increased urinary excretion of colistin when co-administered with a megalin-shedding agent (maleic
acid), megalin ligands (cytochrome c and FRALB), or an endocytosis inhibitor (colchicine). The
lower accumulation of colistin in the kidney cortex was accompanied by a substantial decrease in
urinary N-acetyl-β-D-glucosaminidase (NAG) excretion, a marker of renal tubular damage [42].
Megalin has been shown to mediate the reabsorption of other polycationic antibiotics such as
aminoglycosides [43,44]. The work of Suzuki represents the first experimental evidence that colistin
exerts its nephrotoxic effect upon accumulation in the cells.
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Figure 4. Model of colistin re-absorption in proximal tubule cells. After glomerular filtration,
colistin is taken up by proximal tubule cells by facilitative transport mediated by the human
peptide transporter 2 (PEPT2) and the carnitine/organic cation transporter 2 (OCTN2) and by the
megalin-mediated endocytosis.
Recently, two solute carrier membrane proteins (SLCs) were shown to interact with colistin in vitro:
The human peptide transporter 2 (PEPT2, SLC15A2) and the carnitine/organic cation transporter
2 (OCTN2, SLC22A5) [45,46]. A systematic screening in cells transiently transfected with the open
reading frames (ORFs) of a number of facilitative carriers expressed at the luminal side of proximal
tubule cells showed that the transport of the tritiated dipeptide glycyl-sarcosine ([3H]gly-sar) mediated
by PEPT2 was inhibited by polymyxin B (IC50 = 18.3 ± 4.2 µM) and colistin (IC50 = 11.4 ± 3.1 µM).
However, only the transport of polymyxin B was directly measured (Km = 87.3 ± 11.3 µM) [45].
Because a transport inhibitor is not necessarily a substrate of the transporter as well [47], the transport
of colistin mediated by PEPT2 should be directly assessed by analytical methods such as liquid
chromatography-mass spectrometry (LC-MS) or using radiolabeled colistin. Shortly thereafter, HEK293
cells stably transfected with the ORF of the OCTN2 were shown to accumulate more colistin over
time than the respective wild-type cells [46]. OCTN2 is highly expressed at the luminal membrane
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of proximal tubule cells and is the major carrier of carnitine. The transport of carnitine mediated
by OCTN2 is Na+-dependent, whereas that of other organic cations (e.g., tetraetylammine, TEA) is
independent on Na+ [48]. The replacement of NaCl with choline chloride in the transport buffer did
not alter the accumulation of colistin in the cells overexpressing OCTN2, indicating a Na+-independent
transport of colistin [46].
A number of lines of evidence indicate that OCTN2 plays a central role in cellular carnitine uptake.
Indeed, loss of function mutation in the SLC22A5 gene causes systemic carnitine deficiency (OMIM
212140) [49]. A recent characterization of the urinary metabolites of colistin-induced nephrotoxicity
in rats showed that a single intraperitoneal administration of colistin did not result in signs of renal
damage but a 2-4-fold increase in the levels of a number of amino acids (e.g., isoleucine, valine) and
carnitine derivatives in urine (e.g., acetylcarnitine, butyrylcarnitine) [50]. This supports the speculation
for a role of PEPT2 and OCTN2 in colistin reabsorption in vivo. Nevertheless, to better characterize
the actual contribution of PEPT2 and OCTN2 in colistin renal reabsorption, knock-out animals like
the kidney-specific Pept2-null mice or the jvs mouse strain, which carries a spontaneous missense
mutation in the Slc22a5 gene, should be used in further studies [51,52].
6. The Intracellular Fate of Colistin
The information gathered in the last five years on colistin uptake pathways suggests that colistin
exerts its toxic effect upon entering the cells. The high expression level of megalin, PEPT2, and OCTN2
at the luminal side of proximal tubule cells would imply that the accumulation of colistin is particularly
high in these cells, providing an explanation for kidney sensitivity to colistin [53–56]. Using rationally
designed fluorescent probes, Yun and coworkers confirmed that polymyxins accumulated in the
proximal tubule cells [57]. Mice treated with 7.5 or 15 mg of colistin/kg of body weight/day for 7 days
showed signs of apoptosis involving mitochondrial Bcl-2 and Bax, death receptor (upregulation of Fas,
FasL, and Fas-associated death domain), and endoplasmic reticulum (ER) pathways (upregulation of
Grp78/Bip, ATF6, GADD153/CHOP and caspase-12), suggesting that mitochondrial and ER stress
upon colistin exposure [58].
Studies addressing the nature of colistin-induced mitochondrial dysfunction have not yet been
completed. Indeed, neither the in vitro nor the animal studies available can distinguish between
primary and secondary mitochondrial and ER dysfunction induced by colistin. To address this
question, experiments in freshly isolated mitochondria should be performed. In our lab, we isolated
intact mitochondria from mouse kidneys and exposed them to increasing concentrations of colistin.
The mitochondria rapidly depolarized in a dose-dependent manner, suggesting that colistin directly
targets the mitochondria (unpublished data) (Figure 5).
The target of colistin in mitochondria is not known but interesting hints may be gathered from the
studies focused on elucidating the mechanisms of colistin’s antimicrobial activity. Polymyxins inhibit
cellular respiration in Gram-negative and Gram-positive bacteria [59,60]. The prokaryotic respiratory
chain consists of three complexes with quinones and reduced nicotinamide adenine dinucleotide
(NADH) shuttling electrons and protons between large protein complexes [61,62]. In complex
1, three inner membrane respiratory enzymes of the NADH oxidase family have been identified:
proton-translocating NADH-quinone (Q) oxidoreductase (NDH-1), NADH-Q oxidoreductase (NDH-2),
which lacks an energy-coupling site, and the sodium-translocating NADH-Q oxidoreductase [63]. Deris
and colleagues reported that colistin and polymyxin B inhibit the NDH-2 activity in a non-competitive
manner [3]. NDH-2s are the only enzymes performing respiratory NADH:quinone oxidoreductase
activity. For this reason and for being considered absent in mammals, NDH-2s were proposed
as suitable targets for novel antimicrobial therapies [64]. However, a recent phylogenetic analysis
clustered the human protein apoptosis-inducing factor-homologous mitochondrion associated inducer
of death, AMID (AIF-M2) with the prokaryotic NDH-2 family and not in the group containing
the canonic AIF proteins. AIF-M2 has been shown, indeed, to have NADH-Q oxidoreductase
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activity [65–67]. Overall, the effect of colistin on the human AIF-M2 protein and, in general, on
the mitochondrial electron transport chain should be further studied.
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7. Protective Strategies
Although many risk factors for olistin-induced kidney inju y h ve been identified, including
advanced age, concomitant administration of nephrotoxins (e.g., aminoglycosides), and obesity, data
supporting protective strategies t at can widen the therapeutic win ow of this antibi tic are mostly
anecdotal [68,69]. The g wing evid nce that colisti exposure induces oxidative stress in proximal
tubule c lls suggests that a concomitant anti-oxidant strategy could pro ect the kid ey during the
colistin exp sure [58]. In the last decades, several compounds have been tested in animal models as
protective agents ag inst colistin nephrotoxicity (Table 1). While most of them were able to protect the
kidney during colistin exposure, only ascorba e was tested in a small, preliminary, randomized clinical
trial. The prot ctive effect exerted by ascorbic acid against colistin-induced kidney d mage in animals
indirectly supp ts the hypoth sis that colistin can impair the electron flux along the mitochondrial
inner membrane. Ascorbic acid can replace NADH as electron donor [70].
Ascorbic acid is a poten reducing agent and radical sc venger and reduces stable oxygen,
nitrogen, and thyl radic ls [71]. It is believed to sustain he electron transfer across mitochondrial
inn r membrane downhill of the complex IV [72]. 28 pat ents re eiv d colistimethate sodium
(CMS) intravenously at a loading dose of 300 mg (∼10 million IU). Ascorbic acid was adminis ered
intravenously at a dose of 2 g every 12 h, 20 min before CMS, to 13 out of 28 patients (colistin-ascorbic
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acid group). Nephrotoxicity was defined by the Risk, Injury, Failure, Loss of kidney function,
and End-stage kidney disease (RIFLE) classification system. Urinary neutrophil gelatinase-associated
lipocalin (NGAL) and N-acetyl-β-D-glucosaminidase (NAG) were also assessed as markers of renal
damage. The incidence of acute kidney injury was 53.8% and 60.0% (P = NS) in the colistin-ascorbic
acid and colistin groups, respectively. Similarly, the excretion rates of NGAL and NAG, assessed
at different time points, were not significantly different between the colistin-ascorbic acid group
and the colistin group [73]. The study failed to demonstrate the protective role of ascorbic acid in
colistin-induced kidney toxicity [73]. While the clinical study tried to mirror the regimen used in the
animal study, it is not possible to control the intracellular level of colistin and ascorbic acid. It should be
kept in mind that the intracellular accumulation of colistin and ascorbate might differ between species.
Different ascorbate regimens might amplify the small, not significant, protective effect observed in
this study.
Table 1. Effect of antioxidant strategies on colistin pharmacokinetics (PK) and kidney function.
Compounds Species Colistin PK Kidney Function Reference
Ascorbate
rat ⇑ AUC⇑ vd
⇓ NGAL
⇓ apoptosis [74]
human ⇔ AUC ⇔ NGAL⇔ NAG [73]
α-Tocopherol rabbit ND ⇓ sCRE⇓ BUN [75]
Baicalein mouse ND ⇓ BUN⇓ sCRE [76]
Cilastatin mouse ND ⇓ NGAL⇓ KIM-1 [77]
Curcumin rat ND
⇓MDA
⇓ NO
⇓ inflammation
[78]
Gelofusin
mouse ND ⇓ necrosis⇓ inflammation [79]
rat ⇔ AUC⇔ vd ND
Proanthocyanidin rat ND
⇓ BUN
⇓ sCRE
⇓ iNOS
[80]
Luteolin rat ND ⇓ sCRE⇓ apoptosis [81]
Lycopene mouse ND
⇓ sCRE
⇓ BUN
⇓ apoptosis
⇓ necrosis
[82]
Melatonin rat ⇑ AUC⇑ vd
⇓ NGAL
⇓ sCRE [83]
N-acetylcysteine rat ND ⇓ SOD⇓ NO [84,85]
Sylibin rat ND
⇓ NAG
⇓ Urea
⇓ sCRE
⇓ Urate
⇓Na+, K+
[86]
Taurin mouse ND ⇓ sCRE⇓ BUN [87]
Vitamin E rat ND ⇓ uGGT⇓MDA [88]
AUC, area under the curve; BUN, blood urea nitrogen; MDA, malondialdehyde NAG,
N-acetyl-β-D-glucosaminidase; ND, not determined; NGAL, neutrophil gelatinase-associated lipocalin;
NO, nitric oxide; sCRE, serum creatinine; SOD, superoxide dismutase; uGGT, urine γ-glutamyl-transferase; vd,
volume distribution.
Molecules 2019, 24, 653 10 of 14
8. Conclusions
With the currently available drugs, rate of development and approval of new antibiotics, and the
increasing incidence of MDR infections, we will continue to rely on colistin as a last resort treatment
in severe cases of Gram-negative infection within the near future. Patients under colistin treatment
often suffer from other co-morbidities, not to mention having histories of longer-term hospitalization.
It is of particular importance to focus our studies on the molecular and biochemical mechanisms
of colistin-induced nephrotoxicity in order to facilitate the achievement of the best-possible colistin
therapy outcome: loading dose to reduce or even clear the infection in the shortest possible time,
limiting resistance development. Due to the relatively high incidence and quick onset of nephrotoxicity
by treatment with colistin, it is important to (i) more fully understand the molecular effect of colistin
on eukaryotic cells, (ii) elucidate its cellular transport and sub-cellular accumulation, (iii) establish
founded dosing regimens in humans, based on rigorous PK/PD studies rather than empirical evidence,
(iv) and either uncover novel protective agents or establish optimized dosing and application strategies
for potential candidates. This review has discussed some essential old and new findings in colistin
research that can be of particular interest in achieving these goals. Colistin’s effect on lipid membranes,
particularly effects on mitochondria in eukaryotic cells, as well as the potential transporters that
may play a role in colistin accumulation in the kidney cortex should continue to be studied further.
Investing in such research projects for this relatively old drug is rightly justified due to the current
necessity of colistin therapy in a clinical setting for severe MDR infections. Information resulting
from such targeted studies would be of great help for clinicians to put the most efficient curative and
protective strategies for colistin treatment into place.
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